A081801 (Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.
What is the Condition Being Studied?
Cáncer de pulmón de células no pequeñas (CPCNP)
Who Can Participate in the Study?
Adults 18 and older who:
- Have lung cancer that has been removed while on Duke Cancer Study A151216
- Had their surgery between 33-77 days ago
- Are negative for the genetic markers EGRF and ALK
Grupo etario
Adultos
What is Involved?
If you choose to join this study, you will get a random assignment (fair, equal chance) to 1 of 3 groups:
Regardless of group assignment, all study participants will:
- Get check-ups from your doctor every 3 months for the first 2 years after treatment
- Get check-ups from your doctor every 6 months for the 3rd, 4th, and 5th years after treatment
- Get a yearly check-up from your doctor for 5 more years once you hit the 5-year mark after treatment
Altogether, you will continue to see your doctor and study team for 10 years after treatment.
Study Details
Full Title
Alliance A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO
Principal Investigator
Oncólogo
Protocol Number
IRB:
PRO00106593
NCT:
NCT04267848
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción
Participate
Call 919-681-4768